Navigation Links
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease
Date:6/12/2008

ary efficacy endpoint in the induction phase of the study is the attainment of a clinical response defined as a decrease from baseline in the Crohn's Disease Activity Index (CDAI) score of at least 70 points. In a separate clinical trial, Traficet-EN is also being evaluated for patients with celiac disease, a sensitivity to gluten and gluten derivatives in which digestive tract T cells are thought to play an important role.

"We are very pleased to have completed enrollment of more than 430 patients for the PROTECT-1 study at clinical sites in 17 countries worldwide. This represents an important milestone in the development of this promising new drug, as well as an impressive accomplishment by a committed group of investigators throughout the world and our entire clinical team," said Pirow Bekker, M.D., Ph.D., Vice President, Medical and Clinical Affairs of ChemoCentryx. "Following completion of PROTECT-1, our goal is to expeditiously advance additional clinical development of Traficet-EN to support regulatory filings worldwide."

ChemoCentryx's Second-Generation CCR9 Program

ChemoCentryx is also advancing a second-generation, orally-active CCR9 antagonist through preclinical development and anticipates a regulatory filing to enable first-in-human studies on this compound in the second half of the year. Structurally diverse from Traficet-EN, this second-generation CCR9 antagonist strengthens ChemoCentryx's proprietary position in the CCR9 arena, and gives the company the potential to pursue additional gastrointestinal and other clinical indications with discrete compounds.

The CCR9 program is a part of a strategic alliance that ChemoCentryx signed in 2006 with GlaxoSmithKline's Center of Excellence for External Drug Discovery (CEEDD) for the discovery and development of small molecule antagonists targeting four defined chemokine and chemoattractant receptors. Under the terms of the agreement, ChemoCentryx is responsible for advancing produc
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014 Research ... addition of the  "Global Operating Room Equipment ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,An operating ... environment in a healthcare facility used to ... technically advanced equipment, which ensures patient care ...
(Date:8/22/2014)... -- Research and Markets  has announced the addition ... & Technologies" report to their offering. ... or you wish to expand your product line, you,ll ... The authors know you want to make effective product ... generate improved revenues and take market share from your ...
(Date:8/22/2014)... Research and Markets has announced ... Respirators Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Medicine Technology:Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Global and Chinese Particulate Respirators Industry Report 2014 2
... to a report recently issued by the Centers for ... toll from prescription painkiller overdose, Reckitt Benckiser Pharmaceuticals Inc. ... more about the disease of addiction, available options and ... . The new CDC report showed ...
... Calif., Nov. 10, 2011 Telik, Inc. (Nasdaq: ... the 53rd Annual Meeting of the American Society of ... are as follows: Phase 1 ... Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low ...
Cached Medicine Technology:New Report Puts Spotlight on Epidemic of Painkiller Abuse and Need for Patient Education and Resources 2Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology 2
(Date:8/22/2014)... 2014 Top 10 Best SEO ... hosting companies and highly recommended FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ... manager of Top 10 Best SEO Hosting states, ... server hosting supplier. Actually, these companies have outperformed ... and customer support. People can get the best ...
(Date:8/22/2014)... With the stage set for the ... Expo - which will be held in Boston August ... in its online opinion section, Podium. The op-ed ... co-authored by Steven C. Anderson, IOM, CAE, president & ... the MCPHS University School of Pharmacy – Worcester/Manchester. ...
(Date:8/22/2014)... By Amy Norton ... (HealthDay News) -- A growing number of Americans on ... a new study. Researchers found that between 2007 ... Security Disability Insurance benefits were prescribed narcotic painkillers each ... from 21 percent in 2007 to 23 percent in ...
(Date:8/22/2014)... August 22, 2014 Millennium Treatment ... in Lantana, FL, recently launched a new website. ... for information can now find Millennium Treatment Group ... just went live at the beginning of July. ... facility can be found on the website. There’s ...
(Date:8/22/2014)... oncogenic somatic mutation at amino acid 918 in the ... small cell lung cancer (SCLC) tumors and enforced expression ... intracellular signaling and cell growth. , SCLC is a ... all lung cancers and is strongly associated with tobacco ... extensively examined for genomic alterations and targeted therapies are ...
Breaking Medicine News(10 mins):Health News:FatCow Reviews Released by Top10BestSEOHosting.com 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 4Health News:Millennium Treatment Group Has a New Website 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2
... and lack of proper sleep could be threatening thousands ... warns Heart and Stroke Foundation researcher Dr. Brian McCrindle, ... in Toronto. "Sleep disorders in kids are on ... other increasing cardiovascular risk factors such as overweight and ...
... 25, 2010 Young children who consume substantial amounts ... with fluoridated water or by swallowing fluoride toothpaste have ... to research published in the October issue of The ... supported by the National Institute of Dental and Craniofacial ...
... fear some of it unjustified are common among ... as MRSA, according to the results of a small study ... timely, detailed and simple information, the researchers add. ... Pediatrics , underscore the need for healthcare staff to do ...
... Reporter , MONDAY, Oct. 25 (HealthDay News) -- Why is ... the next day one person ends up feeling more tired ... in their genes, a new study suggests. Researchers at ... individuals who test positive for a common gene variant are ...
... Randy Dotinga HealthDay Reporter , MONDAY, Oct. 25 ... -- to be honest about their drug use, a new ... extent of drug use, but this new research finds that ... for drugs or they,re told the results will be confidential. ...
... treated with a combination of hormone therapy and radiation have ... do not receive radiation, according to interim results of the ... session, November 1, 2010, at the 52nd Annual Meeting of ... 1995 to 2005, 1,205 men with high-risk prostate cancer in ...
Cached Medicine News:Health News:Cardiac wakeup call for Canadian kids 2Health News:Cardiac wakeup call for Canadian kids 3Health News:Substantial consumption of fluoride increases chance of mild fluorosis 2Health News:Knowledge gaps, fears common among parents of children with drug-resistant bacteria 2Health News:Knowledge gaps, fears common among parents of children with drug-resistant bacteria 3Health News:How You Handle Lack of Sleep May Be in Your Genes 2Health News:How You Handle Lack of Sleep May Be in Your Genes 3Health News:Teens, Parents Often Lie About Illicit Drug Use 2Health News:Adding radiation to hormone therapy for prostate cancer treatment will increase survival chances 2
Castroviejo "HM" Micro Needle Holder with Tungsten-Carbide Inserts, with catch. Serrated....
Barraquer needle holder, curved, delicate....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Medicine Products: